The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
@article{ACTR8777,
author = {Takahiro Karasaki},
title = {The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC},
journal = {AME Clinical Trials Review},
volume = {2},
number = {0},
year = {2024},
keywords = {},
abstract = {},
issn = {3005-6152}, url = {https://actr.amegroups.org/article/view/8777}
}